MedPath

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

Phase 3
Completed
Conditions
Infection
Pulmonary Complications
Registration Number
NCT00003031
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with aspergillosis.

PURPOSE: Randomized phase III trial to compare the effectiveness of voriconazole with amphotericin B in treating patients with aspergillosis.

Detailed Description

OBJECTIVES: I. Compare the efficacy, safety, and toleration of voriconazole versus amphotericin B (CAB) in the treatment of acute invasive aspergillosis in immunocompromised patients. II. Compare the efficacy, safety, and toleration of voriconazole versus CAB followed by other antifungal therapy in the treatment of acute invasive aspergillosis in immunocompromised patients. III. Compare survival in patients treated with voriconazole versus CAB with or without other antifungal therapy. IV. Investigate resource utilization in patients treated with voriconazole versus CAB with or without other antifungal therapy.

OUTLINE: This is an open label, randomized, multicenter study. Patients are stratified according to center, site of infection, underlying disease, and baseline neutrophil count. Patients are randomized to one of two treatment arms. Arm I: Patients receive voriconazole IV every 12 hours for 7-28 days and continue with oral voriconazole twice a day for a maximum total duration of 12 weeks of therapy. Arm II: Patients receive intravenous amphotericin B daily for at least 2 weeks; treatment continues for a maximum of 12 weeks. Patients discontinued from study drug treatment because of toxicity, intolerance or clinical failure may receive alternative (nonstudy) antifungal therapy. All patients are monitored for a total of 16 weeks.

PROJECTED ACCRUAL: A sufficient number of patients will be accrued so that 212 patients (106 per study arm) will be eligible for the study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
212
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (74)

Hartford Medical Group

🇺🇸

Wethersfield, Connecticut, United States

St. Vincent's Hospital

🇦🇺

Sydney, New South Wales, Australia

Royal Brisbane Hospital

🇦🇺

Brisbane, Queensland, Australia

Alfred Hospital

🇦🇺

Melbourne, Victoria, Australia

Royal Melbourne Hospital

🇦🇺

Parkville, Victoria, Australia

Algemeen Ziekenhuis Middelheim

🇧🇪

Antwerp, Belgium

Institut Jules Bordet

🇧🇪

Brussels, Belgium

Hopital Universitaire Erasme

🇧🇪

Brussels, Belgium

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Universitair Ziekenhuis Gent

🇧🇪

Ghent, Belgium

Scroll for more (64 remaining)
Hartford Medical Group
🇺🇸Wethersfield, Connecticut, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.